Hansa Biopharma AB (OTCPK:HNSBF)
$ 2.83 0 (0%) Market Cap: 240.18 Mil Enterprise Value: 254.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 72/100

Hansa Biopharma AB Carlsquare Life Science Investor Day Transcript

Dec 06, 2023 / NTS GMT
Release Date Price: $3
Matt Shaulis Hansa Biopharma AB;Chief Commercial Officer;US President

&

Thanks so much. Really pleased to join the group this morning and really appreciate the interest in Hansa Biopharma.

Unidentified_1

So please go ahead and do your presentation. And I will be back for the Q&A.

Matt Shaulis Hansa Biopharma AB;Chief Commercial Officer;US President

&

Wonderful. Alright. As mentioned, I serve in the capacity here at Hansa as Chief Commercial Officer and US President. Really excited to join the group here at Carlsquare Life Sciences for this great event. Why don't we go to the next slide, which of course is our disclaimer. I need to briefly show this slide with our forward-looking statements. And then we can jump right into Hansa Biopharma today. We're a commercial stage biopharmaceutical company based out of Lund in the southern part of Sweden where we're enjoying a little bit of light snowfall today, but we have operations in Europe and in the US as well.

Idefirix

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot